Drug intelligence / Profile preview

NCI-9138

Development stage: Discontinued
Lead developer: National Cancer Institute
Modality: Small Molecules
Administration: Intravenous

Overview

NCI-9138 (also known as NSC 710305) is an investigational small molecule therapeutic that was evaluated by the National Cancer Institute (NCI) for the treatment of various malignancies. While specific structural details and its precise molecular target are not widely publicized in contemporary commercial pipelines, it was historically studied in early-phase clinical trials, including those for advanced solid tumors and hematologic malignancies such as chronic lymphocytic leukemia (CLL). The compound was part of the NCI's developmental therapeutics program aimed at identifying novel antineoplastic agents with unique mechanisms of action compared to standard cytotoxic chemotherapies.

Other names: NCI-9138NCI9138NCI 9138NSC 710305NSC710305NSC-710305

Beyond the preview

Go deeper on NCI-9138.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCI-9138.

Explore the full profile